Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Rank in Stocks #26763
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Share Price
$1.30
Last synced: 2023-10-13
Market Cap
$38.02M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Zynerba Pharmaceuticals, Inc. (ZYNE)

Category

Number of shares outstanding for Zynerba Pharmaceuticals, Inc. (ZYNE)
Number of shares outstanding as of August 2026: 0
According to Zynerba Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Zynerba Pharmaceuticals, Inc. (ZYNE) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors